Molbio Diagnostics & Testi Technologies Collaborate to Introduce Saliva-Based Alcohol Test

The globally patented test strip detects alcohol content in saliva and indicates whether it surpasses a specified threshold, providing individuals with a quick and accessible way to monitor their alcohol intake.

In a significant development aimed at addressing global health concerns related to alcohol consumption, Goa-based Molbio Diagnostics, has partnered with Finland’s Testi Technologies to launch PROMILLESS, a cost-effective, saliva-based alcohol test.

The collaboration comes in response to the alarming statistics from the World Health Organisation (WHO), revealing that the harmful use of alcohol contributes to 5.1% of the global burden of disease, resulting in 3 million deaths annually.

PROMILLESS, a user-friendly self-test kit developed in partnership with VTT, the Technical Research Centre of Finland, is a CE-approved class 1 device. 

The globally patented test strip detects alcohol content in saliva and indicates whether it surpasses a specified threshold, providing individuals with a quick and accessible way to monitor their alcohol intake.

Commenting on the same, Sriram Natarajan, CEO of Molbio Diagnostics, said, "The current alcohol test, alongside upcoming tests like glucose and more in the pipeline, will prove to be a game-changer."

Expanding beyond alcohol testing, Testi Technologies is set to enter the human and pet healthcare markets with a forthcoming saliva-based glucose test. Molbio Diagnostics holds the rights to market and sell PROMILLESS globally under its own brand name through the established agreement.

Molbio Diagnostics, a notable player in the Indian medical technology market, is recognised as the first unicorn catering to global medical professionals. Leveraging Truelab's real-time quantitative micro-PCR system, Molbio offers instant PCR testing in labs worldwide.

In other recent developments, Molbio Diagnostics has collaborated with CrisprBits to launch CRISPR-based point-of-care tests. This partnership signifies a significant stride towards accessible, affordable, and reliable diagnostic testing on the frontline, addressing various diseases and health concerns.

CrisprBits, a biotech start-up, brings forth a platform for quick, accurate, and cost-effective point-of-care tests, leveraging RNA guide-based target identification of nucleic acid and the properties of specific Cas enzymes for enhanced efficiency.